Saturday, October 19, 2019 9:08:31 AM
#######
Groundbreaking paper with Cytosorb published in Nature.com: detailed analysis of adsorbed molecular compounds
triggering the hemodynamic instability of blood vessels and subsequent multi organ failure
########################################################################################
Why is this paper groundbreaking? It clarifies the mechanism of action concerning the reversal and prevention of organ damage - which is the root cause for death in the setting of a septic shock. The authors clearly demonstrate, by analyzing the CytoSorb adsorbed mixture of molecules (cytokines, chemokines, pamps, damps, activated complement....), that a very specific and small fraction of these adsorbed and in the blood circulating molecular entities are responsible for the impairment of the circulatory system. This small fraction of circulating and by CytoSorb adsorbed molecules is composed of an till now unidentified protein highly enriched with nucleic acids (free DNA and RNA released by cell damage or maybe intentionally sheded by cells to trap pathogens) in the size range of 15 kilodalton.
The authors tested 39 fractions of molecular material adsorbed from whole blood by CytoSorb by washing this out of the used adsorbers - but just 3 of these 39 fraction had an adverse effect on endothelial function (proper function of the blood vessel lining), while all others had not. The adverse effects are cell death (apoptosis), reduced ATP content (means reduced cellular metabolism) and inhibition of proliferation (means that the endothel will not be repaired after injury).
These findings also explain, why all other trials with other interventions in a sepsis setting finally fail - because the root cause for endothelial failure and patients death is just a small but very specific subset of all released DAMPS and PAMPS and cytokines and LPS and myoglobin/hemoglobin, ...... This does not mean that it is not beneficial to remove these additional signals - because it is also good to interrupt the inflammatory cascade which is of course moderated by cytokines, but it demonstrates that the final mechanism leading to death of a patient by the impairment of the blood vessel system and resulting multi organ failure during sepsis is now more specifically identified and can be managed by CytoSorb. GROUNDBRAKING NEWS for me and the medical community. You can find the paper by Google using the term: “Bioassay for endothelial Damage Mediators Retrieved by Hemoadsorption”. Yahoo didn’t allow to post a link – sorry.
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM